



## Roche's Announcement Regarding giredestrant (Announcement of Phase III persevERA Study Results)

TOKYO, March 10, 2026 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a media release on March 9, regarding the results of the global Phase III clinical trial (persevERA) evaluating giredestrant in estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.

The detailed data will be presented at an upcoming medical meeting.

Please refer to the link below for details of the media release:

Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

<https://www.roche.com/media/releases/med-cor-2026-03-09>

###